Why the study?
The signaling pathway downstream of CDK2 in doxorubicin-induced cardiomyocyte apoptosis remained to be characterized, and whether the same pathway mediates cardiac atrophy was unclear.
Does FOXO1 inhibition prevent doxorubicin-induced cardiomyocyte apoptosis and atrophy in preclinical models?
Does FOXO1 inhibition prevent doxorubicin-induced cardiomyocyte apoptosis and atrophy in preclinical models?
FOXO1 inhibition protects against doxorubicin-induced cardiomyocyte apoptosis and atrophy, identifying it as a potential therapeutic target for managing anthracycline cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Suggests CDK2-FOXO1 pathway as potential cardioprotective target; leaves open whether inhibition improves outcomes in patients.
Xia et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: